The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)|
- functional magnetic resonance imaging of the brain [ Time Frame: baseline, 4 week, & 6 month follow-up ] [ Designated as safety issue: No ]
|Study Start Date:||August 2009|
|Estimated Study Completion Date:||August 2011|
|Estimated Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
Drug: Sapropterin (Kuvan)
20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Other Name: Kuvan
Healthy individuals without phenylketonuria (PKU).
The proposed study is designed to evaluate the hypothesis that functional connectivity may represent an early marker for neurocognitive improvements related to Kuvan treatment. As a first step in the study, 20 patients with PKU who are ≥ 6 years of age will receive baseline functional connectivity magnetic resonance imaging (fcMRI) evaluations before being treated with Kuvan™. Response to Kuvan™ will be monitored for 4 weeks. At the end of 4 weeks, response to Kuvan™ will be reviewed and all 20 patients will receive follow-up fcMRI evaluations. Fifteen patients with a reduction of ≥ 20% in blood phenylalanine will continue in the study and receive a third fcMRI evaluation at the end of 6 months of treatment with Kuvan™. For comparison purposes and to control for possible practice effects in repeated testing, a matched control group of 20 healthy individuals without PKU will used. All 20 of the control subjects will receive baseline and 4-week fcMRI evaluations; fifteen will receive a 6-month evaluation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00964236
|United States, Missouri|
|University of Missouri|
|Columbia, Missouri, United States, 65211|
|Principal Investigator:||Shawn E Christ, Ph.D.||University of Missouri-Columbia|